<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04785573</url>
  </required_header>
  <id_info>
    <org_study_id>Mastiha_oil_GR_477</org_study_id>
    <nct_id>NCT04785573</nct_id>
  </id_info>
  <brief_title>The Effect of Mastiha Oil in Metabolic Syndrome</brief_title>
  <official_title>The Effect of Mastiha Oil in Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harokopio University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harokopio University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mastiha Oil is a 100% natural product of the Mediterranean, extracted from the resin of&#xD;
      Mastiha. Over 90 compounds have been identified in Mastiha oil, with monoterpenes exhibiting&#xD;
      favorable effects in regulating mechanisms of oxidative stress and inflammation. The aim of&#xD;
      this study is to determine the effect of Mastiha oil in adults with Metabolic Syndrome. 90&#xD;
      participants will be allocated to two groups, (45 in intervention group and 45 in control&#xD;
      group). Mastiha oil will be provided in the form of soft gel capsules to the intervention&#xD;
      group, whereas the control group will not consume the capsules. Both groups will receive&#xD;
      standard nutritional counselling. The intervention will last 3 months.&#xD;
&#xD;
      The effects of the intervention will be evaluated via clinical and laboratory markers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood total cholesterol</measure>
    <time_frame>3 months</time_frame>
    <description>Levels will be evaluated pre and prost intervention in both control and intervention groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in insulin sensitivity</measure>
    <time_frame>3 months</time_frame>
    <description>Levels will be evaluated pre and prost intervention in both control and intervention groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood triglycerides</measure>
    <time_frame>3 months</time_frame>
    <description>Levels will be evaluated pre and prost intervention in both control and intervention groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood LDL</measure>
    <time_frame>3 months</time_frame>
    <description>Levels will be evaluated pre and prost intervention in both control and intervention groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in blood CRP</measure>
    <time_frame>3 months</time_frame>
    <description>Levels will be evaluated pre and prost intervention in both control and intervention groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood MPO</measure>
    <time_frame>3 months</time_frame>
    <description>Levels will be evaluated pre and prost intervention in both control and intervention groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood IL-6</measure>
    <time_frame>3 months</time_frame>
    <description>Levels will be evaluated pre and prost intervention in both control and intervention groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood antioxidant potential</measure>
    <time_frame>3 months</time_frame>
    <description>Levels will be evaluated pre and prost intervention in both control and intervention groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mastiha oil</intervention_name>
    <description>1 soft gel capsule of Mastiha oil every day for 3 months</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  30 years &lt; Age &lt; 75 years&#xD;
&#xD;
          -  BMI &gt; 25 kg/ m2&#xD;
&#xD;
          -  Metabolic Syndrome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hepatotoxic Medication&#xD;
&#xD;
          -  Diabetes Mellitus&#xD;
&#xD;
          -  Dysthyroidism, hypopituitarism, Cushing syndrome / disease&#xD;
&#xD;
          -  Pregnancy, lactation&#xD;
&#xD;
          -  Psychiatric or mental disorder&#xD;
&#xD;
          -  Any use of antioxidant-phytochemical rich supplement, vitamin D supplement, nti-, pre-&#xD;
             or pro-biotics within 3 months pre-intervention&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Harokopio University</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>17671</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andriana Kaliora</name>
      <address>
        <city>Athens</city>
        <zip>17671</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harokopio University</investigator_affiliation>
    <investigator_full_name>Andriana C Kaliora</investigator_full_name>
    <investigator_title>Assistant Professor in Foods and Human Nutrition</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

